Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of September 2004. The report primarily incorporates by reference a press release dated September 1, 2004, announcing a senior management appointment. Compugen is a genomics-based drug and diagnostic discovery company that integrates mathematics, computer science, and physics into biological research.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Noam Shani, Ph.D., as Vice President of Biology Research and Development. Dr. Shani joins from Medgenics Inc., where he served as Vice President of Research and Development. He will lead drug research and development activities, including therapeutic protein candidate discovery, selection, validation, and clinical development.
Guidance, Outlook, and Risks
Management commentary indicates confidence that Dr. Shani's experience will accelerate the advancement of therapeutic and diagnostic candidates from discovery into clinical development. The filing includes standard forward-looking statements regarding future growth and success. Identified risks include changes in collaborator relationships, competitive products, technological changes, new product development risks, and the ability to obtain and retain customers.
Key Facts for Investor Verification
- Dr. Noam Shani has been appointed Vice President of Biology Research and Development, reporting directly to the CEO.
- The company's strategy relies on integrating computational technologies with biology for drug and diagnostic discovery.
- Compugen maintains an early-stage in-house pipeline of therapeutic protein candidates and has out-licensed additional discoveries.
- Key partners and customers include Abbott Laboratories, Diagnostic Products Corporation, Novartis, and Pfizer.
- The company operates subsidiaries Keddem Bioscience (small-molecule drug discovery) and Evogene (agricultural biotechnology).